查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1439888

传染病诊断 - 全球市场考量、竞争状况、市场预测（2030）

Infectious Disease Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: 按订单生产 | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

全球传染病诊断市场规模到2022年将达到385.2亿美元，到2030年将达到481亿美元，预测期内（2022-2028年）复合年增长率为3.80%，预计。 该市场的推动因素包括新冠肺炎(COVID-19)、疟疾和伤寒等传染病的爆发、传染病和大流行病发生率的增加，以及越来越注重为最终用户提高传染病诊断的安全性、可用性和易用性预计这些因素将导致预测期内（2024-2030 年）收入显着增长。

传染病诊断市场动态

在传染病诊断市场的显着驱动因素中，传染病的流行已成为市场的重要驱动因素。 例如，根据世界卫生组织 (WHO) (2022) 的数据，2020 年全球约有 3,770 万人感染人类免疫缺乏病毒 (HIV)。 HIV 的诊断测试之一是核酸检测 (NAT)，通常涉及从静脉抽取血液并测试是否存在病毒。 该测试还测量血液样本中的病毒量。

此外，全球传染病和流行病发病率的增加也推动了传染病诊断市场的成长。 例如，史无前例的COVID-19大流行的爆发已成为世界有史以来面临的最危险的挑战之一。 结果是一场人道主义危机，为世界各地的健康和社会经济带来了严重后果。 根据世界卫生组织（2022）的数据，截至 2020 年底，全球已确诊 4,249,488 例 COVID-19 病例，至 2022 年底，确诊病例约 10,124,070 例。 采用定量或即时逆转录聚合酶链反应（qRT-PCR 或 rRT-PCR）和免疫测定等诊断技术来检测 SARS-CoV-2 病毒（COVID-19 的病原体）。

推动传染病诊断市场成长的另一个主要因素是疟疾流行。 例如，根据世界卫生组织（WHO）的最新数据，2020年全球约有2.41亿人患有疟疾。 用吉姆萨染色对患者血液样本进行显微镜检查被认为是确认疟疾的 "黄金标准" 方法。 快速诊断测试是诊断疟疾的快速替代方法。

然而，血液样本在运输和储存过程中污染的风险、缺乏熟练的放血人员以及诊断测试的高昂成本可能会限制传染病诊断市场的成长。

传染病诊断市场出现短期成长，因为在大流行早期阶段，作为防止 COVID-19 传播的必要措施而实施了封锁，并且暂停了常规诊断测试。据报道，已被压制。 此外，由于封锁影响了诊断试剂盒的生产和供应，市场进一步萎缩。 但随后，随着 COVID-19 患者的激增增加了对 COVID-19 检测和其他呼吸道疾病检测的需求，传染病诊断市场略有改善。 此外，随着包括医疗保健行业在内的各行业恢復其他传染病诊断测试等活动，传染病诊断市场在 2024 年至 2030 年预测期内将保持活跃。

传染病诊断市场区隔分析

在传染病诊断市场的技术领域，免疫分析类别预计在预测期（2024-2030 年）市场收入将显着成长。

这可能是因为免疫测定比其他诊断测试具有更好的诊断能力。 免疫测定法在检测传染病方面具有敏感度和特异性，因为它们基于抗原抗体反应。

与其他诊断方法相比，免疫测定更容易取得、更容易使用，并且可以提供更快的诊断。 免疫测定的成本也低于目前用于诊断传染病的高科技设备。

本报告研究和分析了全球传染病诊断市场，提供市场规模和预测、驱动因素和挑战、公司和产品概况等。

目录

第1章传染病诊断市场报告简介

第2章传染病诊断市场摘要

  • 调查范围
  • 市场概览
  • 竞争评估
  • 财务基准

第3章监理分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第4章传染病诊断市场主要因素分析

  • 推动传染病诊断市场的因素
    • 传染病流行
    • 提供多种诊断测试
    • 传染病和流行病的发生率增加
  • 传染病诊断市场的抑制因素与挑战
    • 运送和储存过程中样品污染的风险
    • 诊断测试成本高昂
  • 传染病诊断市场机遇
    • 人工智慧的使用等技术进步
    • 提高快速诊断试剂盒的可用性和可用性

第5章传染病诊断市场波特五力分析

第6章COVID-19对传染病诊断市场的影响分析

第7章传染病诊断市场布置

  • 依类型
    • 产品
    • 服务
  • 按技术
    • 基于遗传物质的测试
    • 免疫分析
    • 微生物培养
    • 其他
  • 依用途
    • 病毒性疾病
    • 细菌性疾病
  • 按最终用户
    • 医院
    • 诊断实验室
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他领域

第 8 章传染病诊断市场：全球公司占有率分析 - 3 至 5 家主要公司

第9章传染病诊断市场公司与产品概况

  • BD
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Abbott
  • bioMerieux SA
  • QIAGEN
  • DiaSorin S.p.A
  • Meridian Bioscience, Inc.
  • Quest Diagnostics
  • Thermo Fisher Scientific Inc.
  • Cepheid
  • Siemens Healthcare GmbH
  • Ortho Clinical Diagnostics
  • Biocare Medical, LLC
  • Bruker
  • Cardinal Health
  • Chembio Diagnostics, Inc
  • Novacyt
  • Trinity Biotech
  • OJ-Bio Limited

第10章KOL观看次数

第 11 章专案方法

第 12 章关于 DelveInsight

第 13 章免责声明与联络我们

Product Code: DIMDCL0565

Infectious Disease Diagnostic Market By Type (Products [Instruments, Reagents And Kits] And Services), By Technology (Genetic Material Based, Immunoassays, Microbial Cultures, And Others) By Application (Viral Diseases, Bacterial Diseses, And Others) By End-User (Hosptials, Diagnostic Labs, And Others) by geography is estimated to register growth at a remarkable CAGR forecast during 2024-2030 owing to surge in prevalence of infectious diseases and growing concern regarding the incidences of pandemic and epidemics

The global infectious disease diagnostics market was valued at USD 38.52 billion in 2022 and is estimated to grow at a CAGR of 3.80% during the forecast period (2022-2028) to reach USD 48.10 billion by 2030. The infectious disease market is slated to witness prosperity owing to factors such as growing prevalence of infectious diseases such as COVID-19, malaria, typhoid, and others, rising incidences of epidemics and pandemics, and the growing focus on improving the safety, affordability, and usability of infectious disease diagnostics for end-users are further expected to result in the appreciable revenue growth in the infectious disease diagnostics market during the forecast period (2024-2030).

Infectious Disease Diagnostics Market Dynamics:

Among the noteworthy drivers of the infectious disease diagnostics market, the rising prevalence of infectious diseases turns out to be the major factor for accelerating the infectious disease diagnostics market. For instance, according to the World Health Organization (WHO) 2022, globally there were around 37.7 million people suffering from human immunodeficiency virus (HIV) in year 2020. One of the diagnostic test for HIV is Nucleic Acid Test (NAT), where the blood is usually drawn from the vein and tested for the presence of virus. The test also measures the viral load in a blood sample.

Further, rising incidences of epidemics and pandemics across the world is going to boost the market growth for infectious disease diagnostics. For example, the unprecedented outbreak of the COVID-19 pandemic became one of the most dangerous challenges the world has ever faced. It resulted in a humanitarian crisis with severe health and socio-economic consequences across the globe. According to WHO 2022, worldwide there have been 4,249,488 confirmed cases of COVID-19 at the end of 2020 and around 10,124,070 cases at the end of 2022. The diagnostic techniques such as Quantitative or Real-time reverse transcription polymerase chain reaction (qRT-PCR or rRT-PCR), immunoassays, and others were employed in the detection of SARS-CoV-2 virus which is the causative agent for COVID- 19.

Another key factor responsible for the growth of the infectious disease diagnostics market is the increasing prevalence of malaria. For instance, as per the latest data provided by the World Health Organization 2022, globally around 241 million people had suffered from malaria in 2020. The microscopic examination of patients' blood specimen using Giemsa stain is considered as the "gold standard" method for confirmation of malaria. Rapid diagnostic tests are alternative and quick method for the diagnosis of malaria.

However, the risk of blood sample contamination during transport and storage, the lack of skilled phlebotomists and high cost of diagnostic tests may act as restraining factors to the infectious disease diagnostics market growth.

The infectious disease diagnostics market reported a short period of restraint in the market growth during the initial phases of the pandemic due to the implementation of lockdown as necessary measures to prevent the spread of COVID-19 infection leading to the suspension of routine diagnostic checkups. Also, during the initial phases owing to the lockdown, the manufacturing and supply of diagnostic kits, and others were affected leading to further decline in the market. But later owing to the tremendous increase in the COVID-19 cases the demand for COVID- 19 testing along with test for other respiratory diseases increased leading to slight improvement in the infectious disease diagnostics market. Moreover, with the resumption of activities including diagnostic tests for other infectious diseases, and others across industries including the healthcare sector, it has been uplifting for the infectious disease diagnostics market during the forecast period from 2024-2030.

Infectious Disease Diagnostics Market Segment Analysis:

Infectious disease diagnostic market by Type (Products [Instruments, Reagents and Kits] and Services), Technology (Genetic material based tests, Immunoassays, Microbial Cultures, and Others) Application (Viral, Bacterial, and Others) End-User (Hospitals, Diagnostic Labs, and Others) Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the technology segment of the infectious disease diagnostics market, the immunoassays category is projected to register a significant growth in the revenue of the infectious disease diagnosis market during the forecast period (2024-2030).

This can be ascribed to the superior diagnostic features associated with the immunoassays over other diagnostic tests. Immunoassays are based on antigen-antibody reactions and therefore they are highly sensitive and specific for the detection of infectious diseases.

Immunoassays are more readily available, accessible, easy to use, and have rapid turnaround time when compared to other methods of disease diagnosis. Also, the immunoassays are less costly than high tech instruments which are currently utilized for infectious disease diagnosis.

Although immunoassays are used as confirmatory tests along with other tests for infectious disease diagnosis but in certain diseases such as Lyme disease, syphilis, and others, they are primary means for disease detection.

Therefore, considering the growing demand for this product type, numerous new products are being launched in the market. In November 2020, Hologic, Inc., received U.S. Food and Drug Administration (FDA) approval for its Aptima® HIV-1 Quant Dx assay which is the first dual-claim assay for both diagnosis and viral load monitoring. Therefore, considering the advantages associated with the immunoassays and their growing popularity among the end-users, this product category is expected to generate considerable revenue thereby pushing the overall growth of the global infectious disease diagnostics market during the forecast period.

North America is expected to dominate the overall Infectious Disease Diagnostics Market:

Among all the regions, North America is expected to lead in revenue generation of global infectious disease diagnostics market. This can be ascribed to the presence of large patient pool associated with infectious diseases including Sexually transmitted diseases (STSs), TB, and others, and a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region. According to Centers for Disease Control and Prevention 2022, it was estimated that around 1,189,700 people aged 13 and above had HIV in the US in 2019.

Another factor contributing in the growth of infectious disease diagnostics is the increasing cases of tuberculosis. For instance, as per the Centers for Disease Control and Prevention 2022, there were around 7,860 cases of TB reported in 2022 in the United States. As per the same source, currently around 13 million people are living with latent TB infection in the US. The Mantoux tuberculin skin test (TST) is widely used for the screening of tuberculosis.

Moreover, the presence of key market players including BD, Abbott, and Thermo Fisher Scientific Inc. among others along with continuous regulatory approvals are likely to increase the demand for infectious disease diagnostics.

For instance, in July 2022 DiaSorin received the US FDA 510(k) clearance for LIAISON® MeMed BV® Test which is intended for differentiating between the viral and bacterial infections.

Therefore, along with the presence of large patient pool in the country, the increasing focus of key manufacturers on launching the new products in the market is expected to bolster the growth of the infectious disease diagnostics market in the United States during the forecast period.

Infectious Disease Diagnostics Market Key Players:

Some of the key market players operating in the Infectious Disease Diagnostics Market includes BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., bioMerieux SA, Abbott, QIAGEN, DiaSorin S.p.A., Meridian Bioscience, Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Cepheid, Siemens Healthcare GmbH, Ortho Clinical Diagnostics, Biocare Medical, LLC, Bruker, Cardinal Health, Chembio Diagnostics, Inc., Novacyt, Trinity Biotech, OJ-Bio Limited, and others.

Recent Developmental Activities in Infectious Disease Diagnostics Market:

In May 2022, BD announced the launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform in the US.

In December 2022, Roche announced the launch of the first infectious disease tests on the Cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark.

In March 2020, Abbott announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes.

Key Takeaways from the Infectious Disease Diagnostics Market Report Study

  • Market size analysis for current infectious disease diagnostics market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the infectious disease diagnostics market.
  • Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened for last 3 years
  • Key companies dominating the global infectious disease diagnostics market.
  • Various opportunities available for the other competitor in the infectious disease diagnostics market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which is the top-performing regions and countries in the current infectious disease diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for infectious disease diagnostics market growth in the coming future?

Target Audience who can be benefited from this Infectious Disease Diagnostics Market Report Study

  • Infectious diseases diagnostic products providers
  • Research organizations and consulting companies
  • Infectious diseases diagnostic -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in infectious diseases diagnostic
  • Various end users who want to know more about the infectious disease diagnostics Market and latest technological developments in the infectious disease diagnostics market.

Frequently Asked Questions for Infectious Disease Diagnostics Market:

1. What are infectious disease diagnostics?

Infectious disease diagnostics comprises of diagnostic tests, assays, instruments, and others that are utilized for the detection and identification of causative agents responsible for the disease.

2. What is the market for the global infectious disease diagnostic?

The global infectious disease diagnostics market was valued at USD 38.52 billion in 2022 and is estimated to grow at a CAGR of 3.80% during the forecast period (2022-2028) to reach USD 48.10 billion by 2030.

3. What are the drivers for the global infectious disease diagnostics market?

The infectious disease diagnostics market is slated to witness prosperity owing to factors such as increase in the prevalence of infectious diseases such as COVID-19, and HIV among others, technological advancements such as use of AI, rising incidences of epidemics and pandemics, and the growing focus on improving the safety and usability of infectious disease diagnostics for end users are further expected to result in the appreciable revenue growth in the infectious disease diagnostics market during the forecast period (2024-2030).

4. Who are the key players operating in the global infectious disease diagnostics market?

Some of the key market players operating in the infectious disease diagnostics market includes BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., bioMerieux SA, Abbott, QIAGEN, DiaSorin S.p.A., Meridian Bioscience, Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Cepheid, Siemens Healthcare GmbH, Ortho Clinical Diagnostics, Biocare Medical, LLC, Bruker, Cardinal Health, Chembio Diagnostics, Inc., Novacyt, Trinity Biotech, OJ-Bio Limited, and others.

5. Which region has the highest share in the infectious disease diagnostics market?

North America is expected to dominate the overall infectious disease diagnostics market during the forecast period, 2024 to 2030. This can be ascribed to the presence of large patient pool associated with multiple infectious diseases such as STS, Tuberculosis, HPV, and others, high tech medical facilities, government initiatives, and a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.

Table of Contents

1.Infectious Disease Diagnostics Market Report Introduction

2. Infectious Disease Diagnostics Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment
  • 2.4. Financial Benchmarking

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Infectious Disease Diagnostics Market Key Factors Analysis

  • 4.1. Infectious Disease Diagnostics Market Drivers
    • 4.1.1. Increasing prevalence of infectious diseases
    • 4.1.2. Availability of multiple diagnostic tests
    • 4.1.3. Increasing incidences of epidemics and pandemics
  • 4.2. Infectious Disease Diagnostics Market Restraints and Challenges
    • 4.2.1. Risk of sample contamination during transport and storage
    • 4.2.2. High cost of diagnostic tests
  • 4.3. Infectious Disease Diagnostics Market Opportunities
    • 4.3.1. Rising technological advancements such as use of AI
    • 4.3.2. Increasing availability and affordability of rapid diagnostic kits

5. Infectious Disease Diagnostics Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Infectious Disease Diagnostics Market

7. Infectious Disease Diagnostics Market Layout

  • 7.1. By Type
    • 7.1.1. Products
      • 7.1.1.1. Instruments
      • 7.1.1.2. Reagents and Kits
    • 7.1.2. Services
  • 7.2. By Technology
    • 7.2.1. Genetic material based tests
    • 7.2.2. Immunoassays
    • 7.2.3. Microbial cultures
    • 7.2.4. Others
  • 7.3. By Application
    • 7.3.1. Viral diseases
    • 7.3.2. Bacterial diseases
    • 7.3.3. Others
  • 7.4. By End-user
    • 7.4.1. Hospitals
    • 7.4.2. Diagnostic Labs
    • 7.4.3. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.1.2. Canada Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.1.3. Mexico Infectious Disease Diagnostics Market in USD million (2021-2030)
    • 7.5.2. Europe
      • 7.5.2.1. France Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.2.2. Germany Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.2.3. United Kingdom Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.2.4. Italy Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.2.5. Spain Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.2.6. Russia Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.2.7. Rest of Europe Infectious Disease Diagnostics Market in USD million (2021-2030)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.3.2. Japan Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.3.3. India Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.3.4. Australia Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.3.5. South Korea Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.3.6. Rest of Asia Pacific Infectious Disease Diagnostics Market in USD million (2021-2030)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.4.2. Africa Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.4.3. South America Infectious Disease Diagnostics Market in USD million (2021-2030)

8. Infectious Disease Diagnostics Market Global Company Share Analysis - Key 3-5 Companies

9. Infectious Disease Diagnostics Market Company and Product Profiles

  • 9.1. BD
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4. Product Listing
    • 9.1.5. Entropy
  • 9.2. Bio-Rad Laboratories, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4. Product Listing
    • 9.2.5. Entropy
  • 9.3. F. Hoffmann-La Roche Ltd
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4. Product Listing
    • 9.3.5. Entropy
  • 9.4. Abbott
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4. Product Listing
    • 9.4.5. Entropy
  • 9.5. bioMerieux SA
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4. Product Listing
    • 9.5.5. Entropy
  • 9.6. QIAGEN
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4. Product Listing
    • 9.6.5. Entropy
  • 9.7. DiaSorin S.p.A
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4. Product Listing
    • 9.7.5. Entropy
  • 9.8. Meridian Bioscience, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4. Product Listing
    • 9.8.5. Entropy
  • 9.9. Quest Diagnostics
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4. Product Listing
    • 9.9.5. Entropy
  • 9.10. Thermo Fisher Scientific Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4. Product Listing
    • 9.10.5. Entropy
  • 9.11. Cepheid
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4. Product Listing
    • 9.11.5. Entropy
  • 9.12. Siemens Healthcare GmbH
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4. Product Listing
    • 9.12.5. Entropy
  • 9.13. Ortho Clinical Diagnostics
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4. Product Listing
    • 9.13.5. Entropy
  • 9.14. Biocare Medical, LLC
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4. Product Listing
    • 9.14.5. Entropy
  • 9.15. Bruker
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4. Product Listing
    • 9.15.5. Entropy
  • 9.16. Cardinal Health
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4. Product Listing
    • 9.16.5. Entropy
  • 9.17. Chembio Diagnostics, Inc
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4. Product Listing
    • 9.17.5. Entropy
  • 9.18. Novacyt
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4. Product Listing
    • 9.18.5. Entropy
  • 9.19. Trinity Biotech
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4. Product Listing
    • 9.19.5. Entropy
  • 9.20. OJ-Bio Limited
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4. Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on Infectious Disease Diagnostics Market
  • Table 3: Infectious Disease Diagnostics Market in Global (2021-2030)
  • Table 4: Infectious Disease Diagnostics Market in Global by Type (2021-2030)
  • Table 5: Infectious Disease Diagnostics Market in Global by Technology (2021-2030)
  • Table 6: Infectious Disease Diagnostics Market in Global by Application (2021-2030)
  • Table 7: Infectious Disease Diagnostics Market in Global by End-user (2021-2030)
  • Table 8: Infectious Disease Diagnostics Market in Global by Geography (2021-2030)
  • Table 9: Infectious Disease Diagnostics Market in North America (2021-2030)
  • Table 10: Infectious Disease Diagnostics Market in North America by Country (2021-2030)
  • Table 11: Infectious Disease Diagnostics Market in the US (2021-2030)
  • Table 12: Infectious Disease Diagnostics Market in Canada (2021-2030)
  • Table 13: Infectious Disease Diagnostics Market in Mexico (2021-2030)
  • Table 14: Infectious Disease Diagnostics Market in Europe (2021-2030)
  • Table 15: Infectious Disease Diagnostics Market in Europe by Country (2021-2030)
  • Table 16: Infectious Disease Diagnostics Market in France (2021-2030)
  • Table 17: Infectious Disease Diagnostics Market in Germany (2021-2030)
  • Table 18: Infectious Disease Diagnostics Market in the United Kingdom (2021-2030)
  • Table 19: Infectious Disease Diagnostics Market in Italy (2021-2030)
  • Table 20: Infectious Disease Diagnostics Market in Spain (2021-2030)
  • Table 21: Infectious Disease Diagnostics Market in Russia (2021-2030)
  • Table 22: Infectious Disease Diagnostics Market in Rest of Europe (2021-2030)
  • Table 23: Infectious Disease Diagnostics Market in APAC (2021-2030)
  • Table 24: Infectious Disease Diagnostics Market in APAC by Country (2021-2030)
  • Table 25: Infectious Disease Diagnostics Market in China (2021-2030)
  • Table 26: Infectious Disease Diagnostics Market in Japan (2021-2030)
  • Table 27: Infectious Disease Diagnostics Market in India (2021-2030)
  • Table 28: Infectious Disease Diagnostics Market in Australia (2021-2030)
  • Table 29: Infectious Disease Diagnostics Market in South Korea (2021-2030)
  • Table 30: Infectious Disease Diagnostics Market in Rest of APAC (2021-2030)
  • Table 31: Infectious Disease Diagnostics Market in Rest of World (2021-2030)
  • Table 32: Infectious Disease Diagnostics Market in RoW by Region (2021-2030)
  • Table 33: Infectious Disease Diagnostics Market in Middle East (2021-2030)
  • Table 34: Infectious Disease Diagnostics Market in Africa (2021-2030)
  • Table 35: Infectious Disease Diagnostics Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on Infectious Disease Diagnostics Market
  • Figure 3: Infectious Disease Diagnostics Market in Global (2021-2030)
  • Figure 4: Infectious Disease Diagnostics Market in Global by Type (2021-2030)
  • Figure 5: Infectious Disease Diagnostics Market in Global by Technology (2021-2030)
  • Figure 6: Infectious Disease Diagnostics Market in Global by Application (2021-2030)
  • Figure 7: Infectious Disease Diagnostics Market in Global by End-User (2021-2030)
  • Figure 8: Infectious Disease Diagnostics Market in Global by Geography (2021-2030)
  • Figure 9: Infectious Disease Diagnostics Market in North America (2021-2030)
  • Figure 10: Infectious Disease Diagnostics Market in North America by Country (2021-2030)
  • Figure 11: Infectious Disease Diagnostics Market in the US (2021-2030)
  • Figure 12: Infectious Disease Diagnostics Market in Canada (2021-2030)
  • Figure 13: Infectious Disease Diagnostics Market in Mexico (2021-2030)
  • Figure 14: Infectious Disease Diagnostics Market in Europe (2021-2030)
  • Figure 15: Infectious Disease Diagnostics Market in Europe by Country (2021-2030)
  • Figure 16: Infectious Disease Diagnostics Market in France (2021-2030)
  • Figure 17: Infectious Disease Diagnostics Market in Germany (2021-2030)
  • Figure 18: Infectious Disease Diagnostics Market in the United Kingdom (2021-2030)
  • Figure 19: Infectious Disease Diagnostics Market in Italy (2021-2030)
  • Figure 20: Infectious Disease Diagnostics Market in Spain (2021-2030)
  • Figure 21: Infectious Disease Diagnostics Market in Russia (2021-2030)
  • Figure 22: Infectious Disease Diagnostics Market in Rest of Europe (2021-2030)
  • Figure 23: Infectious Disease Diagnostics Market in APAC (2021-2030)
  • Figure 24: Infectious Disease Diagnostics Market in APAC by Country (2021-2030)
  • Figure 25: Infectious Disease Diagnostics Market in China (2021-2030)
  • Figure 26: Infectious Disease Diagnostics Market in Japan (2021-2030)
  • Figure 27: Infectious Disease Diagnostics Market in India (2021-2030)
  • Figure 28: Infectious Disease Diagnostics Market in Australia (2021-2030)
  • Figure 29: Infectious Disease Diagnostics Market in South Korea (2021-2030)
  • Figure 30: Infectious Disease Diagnostics Market in Rest of APAC (2021-2030)
  • Figure 31: Infectious Disease Diagnostics Market in Rest of World (2021-2030)
  • Figure 32: Infectious Disease Diagnostics Market in RoW by Region (2021-2030)
  • Figure 33: Infectious Disease Diagnostics Market in Middle East (2021-2030)
  • Figure 34: Infectious Disease Diagnostics Market in Africa (2021-2030)
  • Figure 35: Infectious Disease Diagnostics Market in South America (2021-2030)
  • Figure 36: Market Drivers
  • Figure 37: Market Barriers
  • Figure 38: Marker Opportunities
  • Figure 39: PORTER'S Five Force Analysis